Keyword: patent cliff

Markets & Companies

European Pharmaceutical Outlook 2020

04.02.2020 - Successful innovation and emerging-market demand are underpinning growth in an industry which benefits from powerful secular trends such as ageing populations and more affluent...

Logistics & Supply Chain

Pharma Management Radar survey 2016: Escaping the complexity trap

12.05.2016 - The good old days are gone — at least with regard to simplicity in business life. This is particularly true for life sciences companies affected by trends increasing the complexity...

Markets & Companies

Leaving the Patent Cliff Behind

07.10.2015 - The pharmaceutical industry is entering a period of sustained growth. Prescription drug sales are set to advance at almost 5% a year until 2020, while worldwide prescription drug...

Strategy & Management

Discovering the Future of Pharma

30.09.2014 - Dramatic changes to the scientific and business environments have made it impossible for pharmaceutical companies to continue operating as they have in the past. A perceived...

Strategy & Management

Camelot’s Pharma Management Radar

23.04.2014 - Power Of The Unknown - Despite a generally positive estimation of the current business climate, global pharmaceutical companies face challenges that endanger their business...

News

Pharmaceutical industry and the VUCA challenges

14.02.2014 - Increasing price pressures on established pharmaceutical markets are requiring extensive adjustments to pharmaceutical business models and the growth rates of most emerging market...

Plant Construction & Process Technology

Camelot’s Pharma Management Radar

24.10.2013 - End Of Patent Protection - The global pharmaceutical industry is steering toward the patent cliff: Some of the biggest blockbuster drugs in history - Lipitor, Plavix and Viagra -...

Plant Construction & Process Technology

Pharma in the Outcome Era

25.09.2013 - Change Is Happening - Pharma is entering the outcome era. Today, launching a new drug means the companies are forced to make much more effort to prove the drug's additional value...